A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

This study is testing GFH375 — a new targeted drug — combined with either cetuximab (a targeted antibody) or chemotherapy, for people whose solid tumors carry a specific genetic mutation called KRAS G12D. **You may be eligible if...** - You are 18 or older (some treatment arms up to age 75) - You have confirmed advanced or metastatic solid tumor cancer with a KRAS G12D gene mutation - Your cancer has not responded to standard treatments, or you cannot tolerate them - You are in adequate physical health to receive treatment **You may NOT be eligible if...** - Your tumor does not have the KRAS G12D mutation - You have significant heart, liver, or kidney problems - You have active brain metastases that are unstable - You have had prior treatment that disqualifies participation Talk to your doctor to see if this trial is right for you.